Status: Recruiting
A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.
Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Intelligem Therapeutics Australia Pty Ltd.Updated: Feb 3, 2026Locations: 6
Eligibility criteria
Male or female, aged 18 to 75 years (both inclusive). [+5]
Prior uricase/recombinant uricase (such as Rasburicase or Pegloticase) therapy w... [+21]